Low Infection Rates With Long‐Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open‐Label Extension Study
Pediatric Dermatology · 2025
DOI: 10.1111/pde.15781 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Pediatric Dermatology, 2025. Verfasst von Amy S Paller und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Objective
To evaluate long‐term infection rates in children aged 6 months to 5 years with moderate‐to‐severe atopic dermatitis (AD) treated with dupilumab.
Methods
This was a post hoc analysis of an ongoing open‐label extension (OLE) study of dupilumab. Pediatric patients aged 6 months to 5 years with moderate‐to‐severe AD who had previously taken part in the LIBERTY AD PRESCHOOL phase 2 and 3 clinical trials received weight‐based subcutaneous dupilumab every 2 or 4 weeks. Exposure‐adjusted infection rates after a median dupilumab exposure of 52 weeks are compared with data from the earlier randomized, placebo‐controlled, 16‐week LIBERTY AD PRESCHOOL phase 3 trial.
Results
Infection rates were overall lower in the OLE study compared with the dupilumab and placebo groups in the earlier 16‐week trial, including total infections (101.0 patients/100 patient‐years [PY]), nonherpetic skin infections (22.7 patients/100PY), herpetic infections (7.3 patients/100PY), and nonskin infections (92.9 patients/100PY). The frequency of severe and serious infections was low (3.1 patients/100PY), compared with 17.1 placebo‐treated patients/100PY and 0 dupilumab‐treated patients in the earlier 16‐week trial, and no infections leading to treatment discontinuation were observed. Systemic anti‐infective medication use (58.9 patients/100PY) was lower in the OLE study compared with both the dupilumab and placebo groups in the 16‐week trial.
Conclusion
Overall, reduced infection rates are observed in infants and young children with moderate‐to‐severe AD treated with dupilumab long‐term, supporting the known safety profile of dupilumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.
- Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Section of Community Pediatrics, Department of Pediatrics, Alberta Children's Hospital, Calgary, Alberta, Canada.
- Sheffield Dermatology Research, University of Sheffield, Sheffield, UK.
- Sheffield Children's Hospital, Sheffield, UK.
ORCID-Profile: Michele Ramien, Sonya L Cyr
Förderung
- Sanofi
- Regeneron Pharmaceuticals
Zitieren
APA
Paller, A. S., Ramien, M., Cork, M. J., Simpson, E. L., Wine Lee, L., Eichenfield, L. F., Khokhar, F. A., Coleman, A., Gherardi, G., Chen, Z., Zhang, A., & Cyr, S. L. (2025). Low Infection Rates With Long‐Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open‐Label Extension Study. Pediatric Dermatology. https://doi.org/10.1111/pde.15781
Vancouver
Paller AS, Ramien M, Cork MJ, Simpson EL, Wine Lee L, Eichenfield LF, et al. Low Infection Rates With Long‐Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open‐Label Extension Study. Pediatric Dermatology. 2025. doi:10.1111/pde.15781
BibTeX
@article{Paller2025,
author = {Paller, Amy S and Ramien, Michele and Cork, Michael J and Simpson, Eric L and Wine Lee, Lara and Eichenfield, Lawrence F and Khokhar, Faisal A and Coleman, Anna and Gherardi, Guy and Chen, Zhen and Zhang, Annie and Cyr, Sonya L},
title = {Low Infection Rates With Long‐Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open‐Label Extension Study},
journal = {Pediatric Dermatology},
year = {2025},
doi = {10.1111/pde.15781}
}
EUVIMED